Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that methylcellulose-based hydrogels can effectively deliver growth hormone through the skin, with albumin increasing the hormone's permeation to 93% in simulated in vivo conditions.

This study presented a refined surgical protocol for a fetal mouse model that improves pregnancy success, reduces fetal loss, and allows for consistent phenotypic outcomes, enhancing research in scarless skin regeneration.

This chapter reviews traction alopecia, discusses its clinical presentation and severity grading, and reports no new clinical results; the authors highlight controversies in its treatment and prevention strategies.

In this study, authors present a case where a 26-year-old patient with alopecia areata experienced relapse after initially responding to Tofacitinib, mitigated by corticosteroids, highlighting challenges and potential insights into the treatment and pathogenesis of the condition.

This article reports a case of rapidly progressive alopecia areata totalis in a COVID-19 patient that did not respond to treatment with tofacitinib; no new clinical results are discussed.

This study observed that oral tofacitinib was effective and safe for treating alopecia areata in paediatric patients, with 82% of pre-adolescent participants experiencing hair regrowth and 64% showing significant improvement in their hair loss severity scores.

This study reported that in a case series of three adolescents with alopecia areata and atopic dermatitis, treatment with 15 mg/day of upadacitinib led to rapid improvement in skin symptoms and significant hair regrowth over 12 months, with no severe adverse events observed.

Alopecia areata patients have more activated T cells in their blood, which may help in developing treatments.

This study in Mexican adolescents with severe alopecia areata reported that oral tofacitinib treatment resulted in hair growth and reduced alopecia severity without serious adverse effects.

In this study, oral tofacitinib was associated with significant hair regrowth in patients with alopecia areata, achieving over 50% reduction in Severity of Alopecia Tool scores, with mild side effects.

This study observed that trichoscopy can identify specific patterns in alopecia areata, such as white and black dots, which assists in non-invasive diagnosis and assessing disease severity.

In this report, trichoscopy was highlighted as a valuable tool for diagnosing temporal triangular alopecia in children due to its ability to reveal distinctive patterns that differentiate it from similar conditions like alopecia areata, eliminating the need for invasive biopsy.

In this study, prophylactic treatment with a neutralizing monoclonal antibody against α-toxin reduced wound sizes and bacterial burden while enhancing healing in both non-diabetic and diabetic mice with S. aureus skin infections.

This abstract does not contain research results or findings.

This study found that oral tofacitinib monotherapy improved nail changes in 73.3% of adults with moderate-to-severe alopecia areata over a median period of 5 months, but nail improvement was not linked to the severity of hair loss or hair regrowth.

Alfredo Rebora suggests a simpler classification for hair loss and a new test for easier diagnosis.

This study found that maintenance treatment with diphenylcyclopropenone was associated with a lower relapse rate in alopecia areata patients, highlighting the importance of adjusting treatment intervals post-improvement.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

This study found that tianeptine may suppress the transition to catagen, promoting hair growth in a stress-induced alopecia areata mouse model.

This review examines current literature on botulinum toxin type A for androgenetic alopecia, reporting an association with increased hair growth and improved hair density, though further research is needed.

This case report describes significant therapeutic effects from Tofacitinib Citrate Sustained-Release Tablets in a patient with Alopecia Areata, while highlighting the economic burden of long-term treatment.

In this study, daily treatment with ritlecitinib for up to 24 months led to significant reductions in high-severity alopecia areata SALT scores among patients aged ≥12 years, including those with severe forms such as alopecia totalis and universalis.

This study recommends limiting routine thyroid function screening to children with alopecia areata who have medical histories of Down syndrome, atopy, or family histories of thyroid disease.

In a single-center study, adolescents with moderate-to-severe alopecia areata treated with ritlecitinib 50 mg daily for 24 weeks showed significant hair regrowth, with 27.3% achieving near-complete regrowth and 45.5% substantial improvement, without serious safety concerns, according to these researchers.

This study reports that a new DART-HRMS method can effectively analyze intact hair for drug use timelines, with cocaine detection aligning with forensic standards and identifying multiple drugs from high-resolution data.

This study found that topical Dithranol 0.5% is more effective than topical Tacrolimus 0.1% for hair regrowth in patients with alopecia areata, with 40% of Dithranol-treated patients showing over 80% hair regrowth compared to 23.33% for Tacrolimus-treated patients.

This report suggests that for prostate cancer patients with cardiovascular disease, prescribing the GnRH antagonist degarelix may reduce cardiac events compared to using GnRH agonists, although prescribing should consider potential cardiac risks, particularly in patients with pre-existing conditions or older age.

The man has Temporal Triangular Alopecia, a stable, non-scarring hair loss condition best treated with hair transplantation.